Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 217 to 226 of 226 entries
Sorted by: Best Match Show Resources per page
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.

Cancer

George DJ, Halabi S, Heath EI, Sartor AO, Sonpavde GP, Das D, Bitting RL, Berry W, Healy P, Anand M, Winters C, Riggan C, Kephart J, Wilder R, Shobe K, Rasmussen J, Milowsky MI, Fleming MT, Bearden J, Goodman M, Zhang T, Harrison MR, McNamara M, Zhang D, LaCroix BL, Kittles RA, Patierno BM, Sibley AB, Patierno SR, Owzar K, Hyslop T, Freedman JA, Armstrong AJ.
PMID: 33951180
Cancer. 2021 Aug 15;127(16):2954-2965. doi: 10.1002/cncr.33589. Epub 2021 May 05.

BACKGROUND: Retrospective analyses of randomized trials suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone acetate plus prednisone to explore outcomes by race.METHODS: This...

Cite
George DJ, Halabi S, Heath EI, et al. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer. 2021;127(16):2954-2965doi: 10.1002/cncr.33589.
George, D. J., Halabi, S., Heath, E. I., Sartor, A. O., Sonpavde, G. P., Das, D., Bitting, R. L., Berry, W., Healy, P., Anand, M., Winters, C., Riggan, C., Kephart, J., Wilder, R., Shobe, K., Rasmussen, J., Milowsky, M. I., Fleming, M. T., Bearden, J., Goodman, M., Zhang, T., Harrison, M. R., McNamara, M., Zhang, D., LaCroix, B. L., Kittles, R. A., Patierno, B. M., Sibley, A. B., Patierno, S. R., Owzar, K., Hyslop, T., Freedman, J. A., & Armstrong, A. J. (2021). A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer, 127(16), 2954-2965. https://doi.org/10.1002/cncr.33589
George, Daniel J, et al. "A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer." Cancer vol. 127,16 (2021): 2954-2965. doi: https://doi.org/10.1002/cncr.33589
George DJ, Halabi S, Heath EI, Sartor AO, Sonpavde GP, Das D, Bitting RL, Berry W, Healy P, Anand M, Winters C, Riggan C, Kephart J, Wilder R, Shobe K, Rasmussen J, Milowsky MI, Fleming MT, Bearden J, Goodman M, Zhang T, Harrison MR, McNamara M, Zhang D, LaCroix BL, Kittles RA, Patierno BM, Sibley AB, Patierno SR, Owzar K, Hyslop T, Freedman JA, Armstrong AJ. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer. 2021 Aug 15;127(16):2954-2965. doi: 10.1002/cncr.33589. Epub 2021 May 05. PMID: 33951180.
Copy Download .nbib Format: NLM
Genetic convergence of developmental and epileptic encephalopathies and intellectual disability.

Developmental medicine and child neurology

Carvill GL, Jansen S, Lacroix A, Zemel M, Mehaffey M, De Vries P, Brunner HG, Scheffer IE, De Vries BBA, Vissers LELM, Mefford HC.
PMID: 34247411
Dev Med Child Neurol. 2021 Dec;63(12):1441-1447. doi: 10.1111/dmcn.14989. Epub 2021 Jul 11.

AIM: To determine whether genes that cause developmental and epileptic encephalopathies (DEEs) are more commonly implicated in intellectual disability with epilepsy as a comorbid feature than in intellectual disability only.METHOD: We performed targeted resequencing of 18 genes commonly implicated...

Cite
Carvill GL, Jansen S, Lacroix A, et al. Genetic convergence of developmental and epileptic encephalopathies and intellectual disability. Dev Med Child Neurol. 2021;63(12):1441-1447doi: 10.1111/dmcn.14989.
Carvill, G. L., Jansen, S., Lacroix, A., Zemel, M., Mehaffey, M., De Vries, P., Brunner, H. G., Scheffer, I. E., De Vries, B. B. A., Vissers, L. E. L. M., & Mefford, H. C. (2021). Genetic convergence of developmental and epileptic encephalopathies and intellectual disability. Developmental medicine and child neurology, 63(12), 1441-1447. https://doi.org/10.1111/dmcn.14989
Carvill, Gemma L, et al. "Genetic convergence of developmental and epileptic encephalopathies and intellectual disability." Developmental medicine and child neurology vol. 63,12 (2021): 1441-1447. doi: https://doi.org/10.1111/dmcn.14989
Carvill GL, Jansen S, Lacroix A, Zemel M, Mehaffey M, De Vries P, Brunner HG, Scheffer IE, De Vries BBA, Vissers LELM, Mefford HC. Genetic convergence of developmental and epileptic encephalopathies and intellectual disability. Dev Med Child Neurol. 2021 Dec;63(12):1441-1447. doi: 10.1111/dmcn.14989. Epub 2021 Jul 11. PMID: 34247411.
Copy Download .nbib Format: NLM
Neural Resources Supporting Language Production vs. Comprehension in Chronic Post-stroke Aphasia: A Meta-Analysis Using Activation Likelihood Estimates.

Frontiers in human neuroscience

LaCroix AN, James E, Rogalsky C.
PMID: 34759804
Front Hum Neurosci. 2021 Oct 25;15:680933. doi: 10.3389/fnhum.2021.680933. eCollection 2021.

In post-stroke aphasia, language tasks recruit a combination of residual regions within the canonical language network, as well as regions outside of it in the left and right hemispheres. However, there is a lack of consensus as to how...

Cite
LaCroix AN, James E, Rogalsky C. Neural Resources Supporting Language Production vs. Comprehension in Chronic Post-stroke Aphasia: A Meta-Analysis Using Activation Likelihood Estimates. Front Hum Neurosci. 2021;15:680933doi: 10.3389/fnhum.2021.680933.
LaCroix, A. N., James, E., & Rogalsky, C. (2021). Neural Resources Supporting Language Production vs. Comprehension in Chronic Post-stroke Aphasia: A Meta-Analysis Using Activation Likelihood Estimates. Frontiers in human neuroscience, 15680933. https://doi.org/10.3389/fnhum.2021.680933
LaCroix, Arianna N, et al. "Neural Resources Supporting Language Production vs. Comprehension in Chronic Post-stroke Aphasia: A Meta-Analysis Using Activation Likelihood Estimates." Frontiers in human neuroscience vol. 15 (2021): 680933. doi: https://doi.org/10.3389/fnhum.2021.680933
LaCroix AN, James E, Rogalsky C. Neural Resources Supporting Language Production vs. Comprehension in Chronic Post-stroke Aphasia: A Meta-Analysis Using Activation Likelihood Estimates. Front Hum Neurosci. 2021 Oct 25;15:680933. doi: 10.3389/fnhum.2021.680933. eCollection 2021. PMID: 34759804; PMCID: PMC8572938.
Copy Download .nbib Format: NLM
Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test.

Aphasiology

LaCroix AN, Tully M, Rogalsky C.
PMID: 34898801
Aphasiology. 2021;35(10):1318-1333. doi: 10.1080/02687038.2020.1795077. Epub 2020 Jul 22.

BACKGROUND: Attention deficits frequently accompany language impairments in aphasia. Most research on attention in aphasia focuses on selective attention measured by executive control tasks such as the color-word Stroop or Erickson flanker. This is despite ample evidence in neurotypical...

Cite
LaCroix AN, Tully M, Rogalsky C. Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test. Aphasiology. 2020;35(10):1318-1333doi: 10.1080/02687038.2020.1795077.
LaCroix, A. N., Tully, M., & Rogalsky, C. (2021). Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test. Aphasiology, 35(10), 1318-1333. https://doi.org/10.1080/02687038.2020.1795077
LaCroix, Arianna N, et al. "Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test." Aphasiology vol. 35,10 (2021): 1318-1333. doi: https://doi.org/10.1080/02687038.2020.1795077
LaCroix AN, Tully M, Rogalsky C. Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test. Aphasiology. 2021;35(10):1318-1333. doi: 10.1080/02687038.2020.1795077. Epub 2020 Jul 22. PMID: 34898801; PMCID: PMC8654326.
Copy Download .nbib Format: NLM
Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test.

Aphasiology

LaCroix AN, Tully M, Rogalsky C.
PMID: 34898801
Aphasiology. 2021;35(10):1318-1333. doi: 10.1080/02687038.2020.1795077. Epub 2020 Jul 22.

BACKGROUND: Attention deficits frequently accompany language impairments in aphasia. Most research on attention in aphasia focuses on selective attention measured by executive control tasks such as the color-word Stroop or Erickson flanker. This is despite ample evidence in neurotypical...

Cite
LaCroix AN, Tully M, Rogalsky C. Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test. Aphasiology. 2020;35(10):1318-1333doi: 10.1080/02687038.2020.1795077.
LaCroix, A. N., Tully, M., & Rogalsky, C. (2021). Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test. Aphasiology, 35(10), 1318-1333. https://doi.org/10.1080/02687038.2020.1795077
LaCroix, Arianna N, et al. "Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test." Aphasiology vol. 35,10 (2021): 1318-1333. doi: https://doi.org/10.1080/02687038.2020.1795077
LaCroix AN, Tully M, Rogalsky C. Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test. Aphasiology. 2021;35(10):1318-1333. doi: 10.1080/02687038.2020.1795077. Epub 2020 Jul 22. PMID: 34898801; PMCID: PMC8654326.
Copy Download .nbib Format: NLM
Latent Adrenal Insufficiency: From Concept to Diagnosis.

Frontiers in endocrinology

Younes N, Bourdeau I, Lacroix A.
PMID: 34512551
Front Endocrinol (Lausanne). 2021 Aug 27;12:720769. doi: 10.3389/fendo.2021.720769. eCollection 2021.

Primary adrenal insufficiency (PAI) is a rare disease and potentially fatal if unrecognized. It is characterized by destruction of the adrenal cortex, most frequently of autoimmune origin, resulting in glucocorticoid, mineralocorticoid, and adrenal androgen deficiencies. Initial signs and symptoms...

Cite
Younes N, Bourdeau I, Lacroix A. Latent Adrenal Insufficiency: From Concept to Diagnosis. Front Endocrinol (Lausanne). 2021;12:720769doi: 10.3389/fendo.2021.720769.
Younes, N., Bourdeau, I., & Lacroix, A. (2021). Latent Adrenal Insufficiency: From Concept to Diagnosis. Frontiers in endocrinology, 12720769. https://doi.org/10.3389/fendo.2021.720769
Younes, Nada, et al. "Latent Adrenal Insufficiency: From Concept to Diagnosis." Frontiers in endocrinology vol. 12 (2021): 720769. doi: https://doi.org/10.3389/fendo.2021.720769
Younes N, Bourdeau I, Lacroix A. Latent Adrenal Insufficiency: From Concept to Diagnosis. Front Endocrinol (Lausanne). 2021 Aug 27;12:720769. doi: 10.3389/fendo.2021.720769. eCollection 2021. PMID: 34512551; PMCID: PMC8429826.
Copy Download .nbib Format: NLM
Unprecedented ON/OFF Ratios in Photoactive Diarylethene-Bisthienylbenzene Molecular Junctions.

Nano letters

Hnid I, Liu M, Frath D, Bellynck S, Lafolet F, Sun X, Lacroix JC.
PMID: 34478314
Nano Lett. 2021 Sep 22;21(18):7555-7560. doi: 10.1021/acs.nanolett.1c01983. Epub 2021 Sep 03.

Photoactive molecular junctions, based on 4 nm thick diarylethene (DAE) and 5 nm thick bisthienylbenzene (BTB) layers, were fabricated by electrochemical deposition. Total thickness was around 9 nm, that is, above the direct tunneling limit and in the hopping...

Cite
Hnid I, Liu M, Frath D, et al. Unprecedented ON/OFF Ratios in Photoactive Diarylethene-Bisthienylbenzene Molecular Junctions. Nano Lett. 2021;21(18):7555-7560doi: 10.1021/acs.nanolett.1c01983.
Hnid, I., Liu, M., Frath, D., Bellynck, S., Lafolet, F., Sun, X., & Lacroix, J. C. (2021). Unprecedented ON/OFF Ratios in Photoactive Diarylethene-Bisthienylbenzene Molecular Junctions. Nano letters, 21(18), 7555-7560. https://doi.org/10.1021/acs.nanolett.1c01983
Hnid, Imen, et al. "Unprecedented ON/OFF Ratios in Photoactive Diarylethene-Bisthienylbenzene Molecular Junctions." Nano letters vol. 21,18 (2021): 7555-7560. doi: https://doi.org/10.1021/acs.nanolett.1c01983
Hnid I, Liu M, Frath D, Bellynck S, Lafolet F, Sun X, Lacroix JC. Unprecedented ON/OFF Ratios in Photoactive Diarylethene-Bisthienylbenzene Molecular Junctions. Nano Lett. 2021 Sep 22;21(18):7555-7560. doi: 10.1021/acs.nanolett.1c01983. Epub 2021 Sep 03. PMID: 34478314.
Copy Download .nbib Format: NLM
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question.

Journal of personalized medicine

Basile V, Puglisi S, Altieri B, Canu L, Libè R, Ceccato F, Beuschlein F, Quinkler M, Calabrese A, Perotti P, Berchialla P, Dischinger U, Megerle F, Baudin E, Bourdeau I, Lacroix A, Loli P, Berruti A, Kastelan D, Haak HR, Fassnacht M, Terzolo M.
PMID: 33916613
J Pers Med. 2021 Apr 04;11(4). doi: 10.3390/jpm11040269.

A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal duration of adjuvant mitotane treatment. We tried to address this question, assessing whether a correlation exists between the duration of adjuvant mitotane treatment and recurrence-free survival...

Cite
Basile V, Puglisi S, Altieri B, et al. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. J Pers Med. 2021;11(4)doi: 10.3390/jpm11040269.
Basile, V., Puglisi, S., Altieri, B., Canu, L., Libè, R., Ceccato, F., Beuschlein, F., Quinkler, M., Calabrese, A., Perotti, P., Berchialla, P., Dischinger, U., Megerle, F., Baudin, E., Bourdeau, I., Lacroix, A., Loli, P., Berruti, A., Kastelan, D., Haak, H. R., Fassnacht, M., & Terzolo, M. (2021). What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. Journal of personalized medicine, 11(4), . https://doi.org/10.3390/jpm11040269
Basile, Vittoria, et al. "What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question." Journal of personalized medicine vol. 11,4 (2021). doi: https://doi.org/10.3390/jpm11040269
Basile V, Puglisi S, Altieri B, Canu L, Libè R, Ceccato F, Beuschlein F, Quinkler M, Calabrese A, Perotti P, Berchialla P, Dischinger U, Megerle F, Baudin E, Bourdeau I, Lacroix A, Loli P, Berruti A, Kastelan D, Haak HR, Fassnacht M, Terzolo M. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. J Pers Med. 2021 Apr 04;11(4). doi: 10.3390/jpm11040269. PMID: 33916613; PMCID: PMC8066814.
Copy Download .nbib Format: NLM
Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test.

Aphasiology

LaCroix AN, Tully M, Rogalsky C.
PMID: 34898801
Aphasiology. 2021;35(10):1318-1333. doi: 10.1080/02687038.2020.1795077. Epub 2020 Jul 22.

BACKGROUND: Attention deficits frequently accompany language impairments in aphasia. Most research on attention in aphasia focuses on selective attention measured by executive control tasks such as the color-word Stroop or Erickson flanker. This is despite ample evidence in neurotypical...

Cite
LaCroix AN, Tully M, Rogalsky C. Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test. Aphasiology. 2020;35(10):1318-1333doi: 10.1080/02687038.2020.1795077.
LaCroix, A. N., Tully, M., & Rogalsky, C. (2021). Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test. Aphasiology, 35(10), 1318-1333. https://doi.org/10.1080/02687038.2020.1795077
LaCroix, Arianna N, et al. "Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test." Aphasiology vol. 35,10 (2021): 1318-1333. doi: https://doi.org/10.1080/02687038.2020.1795077
LaCroix AN, Tully M, Rogalsky C. Assessment of alerting, orienting, and executive control in persons with aphasia using the Attention Network Test. Aphasiology. 2021;35(10):1318-1333. doi: 10.1080/02687038.2020.1795077. Epub 2020 Jul 22. PMID: 34898801; PMCID: PMC8654326.
Copy Download .nbib Format: NLM
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH.
PMID: 34112709
Clin Cancer Res. 2021 Aug 15;27(16):4574-4586. doi: 10.1158/1078-0432.CCR-21-1047. Epub 2021 Jun 10.

PURPOSE: CD40 activation is a novel clinical opportunity for cancer immunotherapy. Despite numerous active clinical trials with agonistic CD40 monoclonal antibodies (mAb), biological effects and treatment-related modulation of the tumor microenvironment (TME) remain poorly understood.PATIENTS AND METHODS: Here, we...

Cite
Byrne KT, Betts CB, Mick R, et al. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021;27(16):4574-4586doi: 10.1158/1078-0432.CCR-21-1047.
Byrne, K. T., Betts, C. B., Mick, R., Sivagnanam, S., Bajor, D. L., Laheru, D. A., Chiorean, E. G., O'Hara, M. H., Liudahl, S. M., Newcomb, C., Alanio, C., Ferreira, A. P., Park, B. S., Ohtani, T., Huffman, A. P., Väyrynen, S. A., Dias Costa, A., Kaiser, J. C., Lacroix, A. M., Redlinger, C., Stern, M., Nowak, J. A., Wherry, E. J., Cheever, M. A., Wolpin, B. M., Furth, E. E., Jaffee, E. M., Coussens, L. M., & Vonderheide, R. H. (2021). Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(16), 4574-4586. https://doi.org/10.1158/1078-0432.CCR-21-1047
Byrne, Katelyn T, et al. "Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,16 (2021): 4574-4586. doi: https://doi.org/10.1158/1078-0432.CCR-21-1047
Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021 Aug 15;27(16):4574-4586. doi: 10.1158/1078-0432.CCR-21-1047. Epub 2021 Jun 10. PMID: 34112709; PMCID: PMC8667686.
Copy Download .nbib Format: NLM
Showing 217 to 226 of 226 entries